IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

氟达拉滨 医学 细胞因子释放综合征 背景(考古学) 内科学 耐受性 耐火材料(行星科学) 淋巴瘤 免疫学 B细胞 肿瘤科 胃肠病学 不利影响 嵌合抗原受体 化疗 环磷酰胺 免疫疗法 癌症 生物 抗体 古生物学 天体生物学
作者
Yugang Guo,Qianwen Xu,Lei Xue,Erlin Chen,Xuhan Zhang,Chonglin Liu,Min Gao,Y F Li,Jingjing Ren,Karthik Sathiyanadan,Li Tang,He Huang,Yongxian Hu,Xingbing Wang
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 92-92 被引量:13
标识
DOI:10.1182/blood-2024-206439
摘要

Context: Despite the undeniable success of CAR-T therapy in treating hematological malignancies, persistent challenges such as ineffectiveness and relapse after remission are observed, often due to CAR-T cell exhaustion and dysfunction. To address these issues, metabolically armored CAR-T cells expressing IL-10 have demonstrated significant improvements in the proliferation and persistence of CAR-T cells in vivo. These engineered cells exhibit remarkable resistance to exhaustion and elicit stem-like memory responses in animal models, resulting in robust tumor eradication and durable protection. To further evaluate both efficacy and safety, we have initiated an open-label, single-arm, investigator-initiated phase I trial (NCT06277011) of IL-10 expressing CD19 CAR-T cells, denoted as Meta10-19, targeting patients with relapsed or refractory B-cell hematological malignancies. Objective: The primary objective of this phase I trial is to assess the safety and tolerability of Meta10-19 among patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL). Secondary goals encompass investigating pharmacokinetics and gauging initial efficacy outcomes. Methods: From February 2023 to July 2024, we enrolled and treated a total of 20 eligible patients with elapsed or refractory B-cell hematological malignancies, including 10 patients with DLBCL and 10 patients with B-ALL. Patients received a single infusion of Meta10-19 across multiple dose level (DL) cohorts from 2.0×104 cells/kg to 2.0×105 cells/kg. The administration followed a standard lymphodepletion regimen involving 30 mg/m2/day fludarabine for 3 days, and 300 mg/m2/day cyclophosphamide for 3 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to Lee 2014 and ASTCT 2019 guidelines, respectively. Adverse events (AEs) were assessed based on CTCAE 5.0 criteria. Results: As of July 16, 2024, Meta10-19 had been successfully infused into 20 eligible patients, who subsequently underwent comprehensive safety and preliminary efficacy evaluations. The median age of the cohort was 50 years (range 17-65). CAR-T cells reached their expansion peak at about 12 days for both DLBCL and B-ALL patients. Remarkably, the complete response (CR) rate for all 20 patients was 100% (20/20), sustained at 100% for 3 months (19/19), and maintained at 94.11% at 6 months (16/17) post-treatment, which is much higher than commercial products (approximately 50% at 6 months post-treatment). Notably, 5 patients have been surviving over 12 months, with the longest observed remission duration to date being 17 months. Treatment-related adverse events, predominantly neutropenia, thrombocytopenia, and anemia, were manageable and effectively resolved with standard and supportive care. Summary: This first-in-human trial of Meta10-19 has demonstrated encouraging preliminary efficacy and a manageable safety profile. Notably, Meta10-19 exhibited a significantly higher CR rate compared to commercial products. Additionally, it provided substantial long-term survival benefits for infused cancer patients, especially at 6 months post-treatment. Ongoing investigations with larger patient cohorts and extended follow-up periods aim to provide further insight into the efficacy and safety parameters.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
molihuakai的应助被尔尔采纳,获得10
1秒前
无敌完成签到,获得积分10
1秒前
NexusExplorer的应助被正直凡灵采纳,获得10
2秒前
2秒前
3秒前
Liew完成签到 ,获得积分10
4秒前
zo发布了新的文献求助10
4秒前
甜美沛容发布了新的文献求助10
4秒前
4秒前
5秒前
木子发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
7秒前
7秒前
冷傲的白柏完成签到,获得积分10
8秒前
霁月发布了新的文献求助10
9秒前
9秒前
自由的雪一完成签到,获得积分10
9秒前
10秒前
Olive发布了新的文献求助10
10秒前
完美世界的应助被六月雪采纳,获得10
11秒前
11秒前
霁月发布了新的文献求助10
12秒前
12秒前
霁月发布了新的文献求助10
12秒前
霁月发布了新的文献求助10
12秒前
霁月发布了新的文献求助10
12秒前
ZZKKZZ发布了新的文献求助10
12秒前
13秒前
13秒前
14秒前
15秒前
16秒前
所所的应助被dieeee采纳,获得10
16秒前
科研通AI2S的应助被清秀千兰采纳,获得10
17秒前
17秒前
小SCI发布了新的文献求助10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541